The Neuroendocrine Tumor Research Foundation (NETRF) welcomes five new members to its Board of Scientific Advisors (BOSA), a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the understanding, diagnosis, and treatment of neuroendocrine cancer.
“The new NET experts joining BOSA in 2020 increase the diversity of experience on our scientific advisory board,” said John Kanki, PhD, NETRF Director of Research. “We now have greater representation of translational researchers and are excited to add a member with extensive experience in lung NETs.”
2020 appointments to the NETRF Board of Scientific Advisors:
Bradley E. Bernstein, MD, PhD
Harvard Medical School, Massachusetts General Hospital
James A. Bibb, PhD
University of Alabama at Birmingham Medical Center
Guillermina (Gigi) Lozano, PhD
University of Texas MD Anderson Cancer Center
John D. Minna, MD
University of Texas (UT) Southwestern Medical Center
Dawn E. Quelle, PhD
Holden Comprehensive Cancer Center, University of Iowa College of Medicine
The BOSA is central to the rigorous scientific review that allows NETRF to quickly identify the most promising grant applications and fund projects that have the most potential to transform the NET landscape. In addition, the BOSA provides leadership for and participation in the annual NETRF Research Symposium.
All members of the NETRF Board of Scientific Advisors are recognized experts in medical research, published authors in the top peer-reviewed medical journals, and principal investigators of collaborative research projects at top-ranked universities and institutes.